Artificial intelligence for aging research in cancer drug development

A new editorial paper was published in Aging, entitled, “Artificial intelligence for aging research in cancer drug development.”

Aging is a multifactorial and complex process associated with various diseases, including cancer. In light of the growing aging population, the need for effective cancer treatments is more significant than ever. Artificial intelligence (AI) plays an increasingly crucial role in aging research and cancer drug development in revealing the critical drivers of outcomes among a wide range of intrinsic and extrinsic factors.

In recent years, the use of AI in aging research has been rapidly increasing, suggesting that AI-based analysis of health care data may enhance clinical care.

In this new editorial, researchers Dorsa Shirini, Lawrence H. Schwartz, and Laurent Dercle from Columbia University Medical Center provide an overview of the potential benefits as well as the technical caveats of adopting AI to help researchers identify new targets, develop more effective therapies, and accelerate the discovery process of drug development in the context of aging research.

“In this review, we discuss how we could leverage AI technologies to consider a patient’s unique aging profile and tailor cancer treatment more precisely to the individual. This approach would help optimize treatment outcomes, minimize treatment-related risks, and improve the overall quality of care for patients, considering the complex interplay between aging and cancer treatment response.”

Provided by
Impact Journals LLC